Six-Week Treatment?

December 3, 2015 By Benjamin Ryan

A Phase II trial of Achillion's investigational hep C treatment odalasvir (ACH-3102) and Gilead Sciences' Sovaldi (sofosbuvir) has shown promise that a six-week hepatitis C treatment may be on the horizon.

The study included people with genotype 1 of the virus who had not been treated before. All 24 of the participants who took the regimen for six weeks were cured. The treatment proved well tolerated.

Kris Kowdley, MD, a liver specialist at Swedish Medical Center in Seattle, says, "This regimen seems promising, and we would be interested in seeing more data"—in particular to more precisely determine how short of a treatment length will provide good results.

© 2026 Smart + Strong All Rights Reserved.
http://beta.docker.hepmag.com/article/six-week-treatment-28120-1465908406